Analysis Note
ControlIncludes negative control mouse IgG antibody and control primers specific for the cDNA of human JUN.
Application
Immunoprecipitation from RIP lysate:
Representative lot data.
RIP lysate from HeLa cells (~2 X 10E7 cell equivalents per IP) was subjected to immunoprecipitation using 5 µg of either a normal mouse IgG, (Cat. #CS200621), or 5 µg of Anti-FXR1 antibody (Cat. # CS204403). Ten percent of the precipitated proteins (lane 1: T7, lane 2: mouse IgG, lane 4: FXR1) and HeLa whole cell lysate (lane 3) were resolved by electrophoresis, transferred to nitrocellulose and probed with anti-FXR1 antibody (Cat. # CS204403, 1:1000).
Proteins were visualized using One-Step™ IP-Western kit (GenScript Cat. # L00232).
Arrow indicates Aly/REF (~68 kDa) (Figure 2).
Western Blot Analysis:
Representative lot data.
HeLa cell lysate was resolved by electrophoresis, transferred to PVDF membranes and probed with anti-FXR1 (0.5 µg/mL) dilution.
Proteins were visualized using a Goat anti-mouse IgG conjugated to HRP using a chemiluminescence detection system.
Arrow indicates FXR1 (~68 kDa) (Figure 3).
Immunocytochemistry Analysis:
Representative lot data. A 1:500 dilution from a representative lot detected FXR1 in HeLa and NIH/3T3 cell lysates. Nucleus is stained with DAPI (Blue). This antibody positively stains the Cytoplasm (Figure 4).
Immunoprecipitation Analysis:
A representative lot was used in an independent laboratory in immunoprecipitation. (Siomi, M., et al. (1996). Molecular and Cellular Biology. 3825-3832).
Research CategoryEpigenetics & Nuclear Function
Research Sub CategoryRNA Metabolism & Binding ProteinsDevelopmental Signaling
This RIPAb+ FXR1 -RIP Validated Antibody & Primer Set conveniently includes the antibody & the specific control PCR primers.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
RIPAb+ antibodies are evaluated using the RNA Binding Protein Immunoprecipitation (RIP) assay. Each RIPAb+ antibody set includes a negative control antibody to ensure specificity of the RIP reaction and is verified for the co-immunoprecipitation of RNA associated specifically with the immunoprecipitated RNA binding protein of interest. Where appropriate, the RIPAb+ set also includes quantitative RT-PCR control primers (RIP Primers) to biologically validate your IP results by successfully co-precipitating the specific RNA targets, such as messenger RNAs. The qPCR protocol and primer sequences are provided, allowing researchers to validate RIP protocols when using the antibody in their experimental context. If a target specific assay is not provided, the RIPAb+ kit is validated using an automated microfluidics-based assay by enrichment of detectable RNA over control immunoprecipitation.
Fragile X mental retardation-related protein 1 (FXR1) and FXR2 are members of the FMR1 family sharing a very high degree of protein similarity among them